MENU
+Compare
IBRN
ETF ticker: NYSE ARCA
AS OF
Dec 19 closing price
Price
$25.37
Change
-$0.83 (-3.17%)
Net Assets
3.83M

IBRN stock forecast, quote, news & analysis

Category: @Health
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
A.I.Advisor
a Summary for IBRN with price predictions
Dec 20, 2024

IBRN sees MACD Histogram just turned negative

IBRN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on December 05, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 21 instances where the indicator turned negative. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 09, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRN as a result. In of 45 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

IBRN moved below its 50-day moving average on December 05, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IBRN crossed bearishly below the 50-day moving average on December 11, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IBRN's RSI Indicator exited the oversold zone, of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 30 cases where IBRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

IBRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 83 cases where IBRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Sarepta Therapeutics (NASDAQ:SRPT), Intra-Cellular Therapies (NASDAQ:ITCI), Avadel Pharmaceuticals plc (NASDAQ:AVDL).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.44B. The market cap for tickers in the group ranges from 22.27M to 37.64B. ARGX holds the highest valuation in this group at 37.64B. The lowest valued company is ATHA at 22.27M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was -2%. For the same ETF, the average monthly price growth was -2%, and the average quarterly price growth was 7%. PRTA experienced the highest price growth at 19%, while LRMR experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 155%. For the same stocks of the ETF, the average monthly volume growth was 179% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 84
Price Growth Rating: 58
SMR Rating: 85
Profit Risk Rating: 81
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com